In Section A, members will receive unique doses and schedules of oral ABBV-744 pill to recognize Harmless dosing regimen. Added contributors will likely be enrolled within the identified monotherapy dosign regimen. In Section B, participants will get oral ruxolitinib and ABBV-744 will probably be presented as "increase-on" therapy. In Segment https://alfredz211kvg3.wikicorrespondence.com/user